drugset
drugset / Trial / NCT04013048

Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor

NCT04013048 ↗

Phase 1 Completed 5 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelOther

Summary

Study to Evaluate the Mass Balance and Biotransformation of Single Dose \[14C\]-FZPL in Chinese Patients with Solid Tumor

Timeline

Start
2019-07-08
Primary completion
2019-12-24
Completion
2019-12-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluzoparib Small molecule — Oral

Indications

cancer